Most primary adrenal lymphomas are diffuse large B-cell lymphomas with non-germinal center B-cell phenotype, BCL6 gene rearrangement and poor prognosis

Abstract

Primary adrenal lymphoma is extremely rare, accounting for o1% of non-Hodgkin lymphomas, and lymphomaassociated chromosomal translocations have yet to be reported in this entity. We performed a retrospective study of 10 cases in immunocompetent patients including 4 males and 6 females with a median age of 68 years. The most common presenting symptoms were abdominal pain and fever; unexpectedly, clinically evident adrenal insufficiency was detected only in one patient. The mean tumor size at diagnosis was 8.5 cm. Half of the patients had bilateral involvement. All cases presented with stage IE disease without regional nodal involvement. Histologically, eight cases were diffuse large B-cell lymphoma, all of which carried a nongerminal center B-cell phenotype. Fluorescence in situ hybridization revealed BCL6 gene rearrangement in 5 (83%) of 6 diffuse large B-cell lymphomas investigated. The remaining cases were one case each of plasmablastic lymphoma and extranodal NK/T-cell lymphoma, nasal type, the first and third case of primary adrenal lymphoma of these particular lymphoma subtypes in the English literature, respectively. At a median follow-up of 4.5 months, 7 patients died of lymphoma, 1 died of an unrelated disease, 1 was alive with disease, and 1 was alive without disease. The prognosis of these patients was poor as compared with those with nodal diffuse large B-cell lymphoma. We speculate that the poor outcome of primary adrenal lymphoma might be related to the bulky tumor size at presentation, non-germinal center B-cell phenotype, and frequent BCL-6 gene rearrangement. Keywords: adrenal insufficiency; diffuse large B-cell lymphoma; NK/T-cell lymphoma; plasmablastic lymphoma; primary adrenal lymphoma; Taiwan Although secondary involvement of the adrenal glands by non-Hodgkin's lymphoma is not uncommon, primary adrenal lymphoma is extremely rare and accounts for o1% of all non-Hodgkin's lymphoma cases. 1 In the English literature, most of the papers on primary adrenal lymphomas are singlecase reports and literature reviews based on a small number of cases except two large series. [1][2][3][4][5] Up to half of the small number of reported patients with primary adrenal lymphoma were associated with adrenal insufficiency and there is a high rate of

Prognostic impact of extranodal involvement in diffuse large B‐cell lymphoma in the rituximab era

“…We identified 8 extranodal sites that have an impact on prognosis, 7 of which are associated with a poor prognosis. Lymphomas with involvement in these sites reportedly tend toward advanced stages, [5][6][7][8][9][10][11] whether defined as primary sites or not. Patients with extranodal involvement of these sites in our cohort also tended to have disseminated disease.…”

A new extranodal scoring system based on the prognostically relevant extranodal sites in diffuse large B-cell lymphoma, not otherwise specified treated with chemoimmunotherapy

“…Based on univariate analysis, these authors also demonstrated that the lung, liver, spleen, kidney, and skin involvement was significant. Furthermore, isolated reports have suggested that involvement of the adrenal glands [21,22], skin [23], and kidney [24] may also be associated with a poor prognosis. Moreover, we showed that a novel extranodal scoring system, using these extranodal sites, may improve the predictability of older risk prediction models.…”

Bilateral Adrenal Primary Diffuse Large B-Cell Lymphoma not Accompanied by Adrenal Insufficiency: A Report of Two Cases

“…Kyung Min Kim et al reported a series of PA-DLBCL cured through Rituximab-CHOP (R-CHOP) chemotherapy, these cases were confirmed of diagnosis through CT guided needle biopsy, and did not undergo surgery treatment [13]. Ana Mozos et al summarized 10 cases of PA-DLBCL patients, which 5 are affected bilaterally, during 4.5 months of random visitations, 7 cases died of lymphoma, 1 died of unrelated disease, 1 survived with the disease, 1 cured and survived [14]. Satoshi Ichikawa et al analyzed 7 cases of PA-DLBCL patients, 5 affected bilaterally, underwent R-CHOP chemotherapy, 2 year survival rate was 57% [15].…”